CN107652227B - 一种n-苄基-3-羟基哌啶的合成方法 - Google Patents
一种n-苄基-3-羟基哌啶的合成方法 Download PDFInfo
- Publication number
- CN107652227B CN107652227B CN201711133635.9A CN201711133635A CN107652227B CN 107652227 B CN107652227 B CN 107652227B CN 201711133635 A CN201711133635 A CN 201711133635A CN 107652227 B CN107652227 B CN 107652227B
- Authority
- CN
- China
- Prior art keywords
- benzyl
- hydroxypiperidine
- synthesizing
- reaction
- trimethylsiloxypiperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UTTCOAGPVHRUFO-UHFFFAOYSA-N 1-benzylpiperidin-3-ol Chemical compound C1C(O)CCCN1CC1=CC=CC=C1 UTTCOAGPVHRUFO-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 238000001308 synthesis method Methods 0.000 title abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims abstract description 22
- -1 N-benzyl-3-trimethylsiloxypiperidine Chemical compound 0.000 claims abstract description 21
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000010511 deprotection reaction Methods 0.000 claims abstract description 8
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 5
- 239000011737 fluorine Substances 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 238000010189 synthetic method Methods 0.000 claims abstract description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 150000007529 inorganic bases Chemical class 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000012044 organic layer Substances 0.000 claims description 5
- 238000004537 pulping Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical group [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical class [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- 125000006278 bromobenzyl group Chemical group 0.000 claims description 2
- 125000004803 chlorobenzyl group Chemical group 0.000 claims description 2
- 125000006277 halobenzyl group Chemical group 0.000 claims description 2
- 239000011698 potassium fluoride Substances 0.000 claims description 2
- 235000003270 potassium fluoride Nutrition 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 4
- 239000003513 alkali Substances 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000003760 magnetic stirring Methods 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 5
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 3
- 229960004916 benidipine Drugs 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 229940073608 benzyl chloride Drugs 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000005574 benzylation reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- VLECDMDGMKPUSK-UHFFFAOYSA-N hydron;piperidin-3-ol;chloride Chemical compound Cl.OC1CCCNC1 VLECDMDGMKPUSK-UHFFFAOYSA-N 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 239000012450 pharmaceutical intermediate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- NCPHGZWGGANCAY-UHFFFAOYSA-N methane;ruthenium Chemical compound C.[Ru] NCPHGZWGGANCAY-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- YNOGYQAEJGADFJ-UHFFFAOYSA-N oxolan-2-ylmethanamine Chemical compound NCC1CCCO1 YNOGYQAEJGADFJ-UHFFFAOYSA-N 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本发明公开了一种N‑苄基‑3‑羟基哌啶的合成方法,属于有机合成技术领域。在碱存在下,3‑羟基哌啶经卤代苄保护后,加入六甲基二硅基胺烷继续反应,得到N‑苄基‑3‑三甲基硅氧基哌啶,接着加入醇类溶剂或含氟离子盐脱保护,得到高纯度N‑苄基‑3‑羟基哌啶。本发明合成方法原料和试剂廉价易得,反应条件温和,可连续操作,产品纯度高达99.5%以上,比较适合规模化放大生产。
Description
技术领域:
本发明属于有机化学技术领域,具体涉及一种N-苄基-3-羟基哌啶的合成方法。
背景技术:
3-羟基哌啶类衍生物广泛用于药物中间体的合成,其中N-苄基-3-羟基哌啶是贝尼地平合成过程中最重要的一个中间体,仅需再通过一步酯化反应就可以获得贝尼地平,贝尼地平是第二代二氢吡啶类钙离子拮抗剂,可以通过阻断L型钙通道起到舒张血管、降低血压、抗心绞痛的作用,近年来,N-苄基-3-羟基哌啶作为医药中间体的市场需求呈快速上升趋势。目前N-苄基-3-羟基哌啶的合成途径主要有以下四类:
1.以3-羟基吡啶为原料,经先苄氯或溴苄烷基化成季铵盐、再还原吡啶环得到N-苄基-3-羟基哌啶(CN101817779,CN10130080),该路线中吡啶季铵盐的还原需要使用还原剂金属氢化物硼氢化钠或金属催化剂加压氢化才能进行,缺点为硼氢化钠做还原剂后处理操作非常危险,容易产生事故,金属催化剂加压氢化反应条件苛刻且催化剂成本较高,两者均不适用于工业化生产。
2.以3-羟基吡啶为原料,先在铑碳或是钌碳等贵金属催化剂作用下高压氢化得到3-羟基哌啶后再N-苄基化,该路线采用贵金属作催化剂,成本较高,而且反应在较高温度和压力(60-120℃,5-10atm)下进行,加之原料和产品对于催化剂活性都存在钝化作用,这些因素均不利于整个工艺路线的成本控制。
3.以苄基四氢糠胺为原料,经浓盐酸成盐后先开环在关环N-苄基-3-羟基哌啶(JP1993-168493),但是该方法有以下几个不足之处:1)原料不易得,苄基四氢糠胺必须通过四氢糠胺还原胺化制备;2)反应的转化率及选择性都不是很好,制备效率低。
4.以3-羟基哌啶盐酸盐为原料,经三乙胺解离后与等当量的氯苄在甲苯中回流反应后,后处理经高真空高温减压蒸馏(125-126℃/3.5mmHg)得到N-苄基-3-羟基哌啶(US4448964),该方法原料转化不完全,副产物苄醇及氧和氮被苄基同时取代的化合物较多,主要副产物氧上接苄基副产物和产物沸点接近,GC上出峰不超过0.2min,很难通过精馏去除,收率仅有56.9%;纯化方法需高温高真空,不适于放大生产。
发明内容:
为了解决以上问题,本发明目的是提供一种N-苄基-3-羟基哌啶的合成方法。在碱存在下,3-羟基哌啶和卤代苄反应后,接着加入六甲基二硅基胺烷,得到N-苄基3-三甲基硅氧基哌啶,随后加入醇类溶剂或含氟离子盐反应,得到高纯度的N-苄基-3-羟基哌啶。
一种N-苄基-3-羟基哌啶的合成方法,其技术特征在于,包括如下步骤:
第一步,将3-羟基哌啶溶于有机溶剂中,加入碱,滴加0.9-0.95当量卤代苄,40~50℃反应;反应结束后,加入六甲基二硅基胺烷,升温至50~100℃反应,减压蒸馏出低沸点物质,向残余物中加入甲基叔丁基醚,过滤掉不溶物,滤液为N-苄基-3-三甲基硅氧基哌啶的甲基叔丁基醚溶液,直接用于下步反应;
第二步,将上述第一步所得N-苄基-3-三甲基硅氧基哌啶缓慢加入醇类溶剂或含氟离子盐脱保护,水洗,有机层减压浓缩后,加入正庚烷-10~0℃下打浆,过滤得到N-苄基-3-羟基哌啶。
反应路线如下:
进一步地,所述第一步中,有机溶剂选自甲苯、丙酮或四氢呋喃。
进一步地,所述第一步中,卤代苄选自溴苄或氯苄。
进一步地,所述第一步中,无机碱选自碳酸钠、碳酸钾或碳酸铯。
进一步地,所述第一步中,3-羟基哌啶、无机碱和六甲基二硅基胺烷的摩尔比为1:1.5-2.5:1.5-2。
进一步地,所述第一步实际为两个阶段,第一阶段,3-羟基哌啶上的氮苄基化生成N-苄基-3-羟基哌啶;第二阶段,六甲基二硅基胺烷使反应液中的第一阶段剩余原料3-羟基哌啶、卤代苄的副产苄醇和产物N-苄基-3-羟基哌啶全部硅烷化,经减压蒸馏蒸出溶剂及副产物除掉杂质,残余物再经溶解过滤除盐得到N-苄基3-三甲基硅氧基哌啶的溶液。
进一步地,所述第二步中,脱保护时所用的醇类为甲醇和乙醇,优先推荐采用甲醇;含氟离子盐为氟化钾或四丁基氟化胺。
本发明的具有以下优势:
1、所述合成方法采用的原料和试剂廉价易得,反应条件温和,各步可连续操作。
2、反应转化率和选择性好,副产物少,反应结束后只需经过简单处理后得到高纯度的产品,避免了高温高真空的减压蒸馏提纯过程。
3、该方法收率高、重现性好、安全可靠,适合放大生产。
具体实施例
实施例1
第一步,在配有磁力搅拌的2L三口瓶内,将3-羟基哌啶(101.2g,1mol)溶于1L甲苯中,加入碳酸钾(276.4g,2mol),滴加0.9当量溴化苄(153.9g,0.9mol),40~50℃反应5小时,GC中控反应完毕;氮气保护下,加入六甲基二硅基胺烷(322.8g,2mol),升温至70~80℃反应2小时,TLC检测反应完毕,展开剂为:正己烷/乙酸乙酯=5∶1,降温,浓缩出溶剂后,减压蒸馏出低沸点物质(42~69℃,2torr),室温下向残余物中加入1.2L甲基叔丁基醚,过滤掉不溶物,滤液为N-苄基-3-三甲基硅氧基哌啶的甲基叔丁基醚溶液,直接用于下步反应,GC纯度:97.6%(扣除溶剂),GCMS(m/z):263.17。
第二步,在配有磁力搅拌的2L三口瓶内,向上述第一步所得N-苄-3-三甲基硅氧基哌啶溶液中,缓慢滴加160mL甲醇,控温10-20℃,滴毕,室温继续搅拌1小时,GC检测脱保护完全后,水洗,有机层减压浓缩后,加入250mL正庚烷-10~0℃下打浆,过滤得到类白色N-苄基-3-羟基哌啶147.3g,两步收率85.6%,熔点25.5-26.9℃,GC纯度99.6%,1H NMR(CDCl3,400MHz)δ(ppm):7.33-7.22(m,5H),3.81-3.76(m,1H),3.49(s,1H),2.67(br,1H),2.52-2.43(m,3H),2.35-2.28(m,1H),1.81-1.73(m,1H),1.63-1.48(m,3H)。
实施例2
第一步,在配有磁力搅拌的2L三口瓶内,将3-羟基哌啶(101.2g,1mol)溶于1L丙酮中,加入碳酸铯(448.7g,1.5mol),滴加0.95当量氯化苄(120.3g,0.95mol),40~50℃反应3小时,GC中控反应完毕;氮气保护下,加入六甲基二硅基胺烷(242.1g,1.5mol),升温回流反应2小时,TLC检测反应完毕,展开剂为:正己烷/乙酸乙酯=5∶1,降温,浓缩出溶剂后,减压蒸馏出低沸点物质(42~69℃,2torr),室温下向残余物中加入1.2L甲基叔丁基醚,过滤掉不溶物,滤液为N-苄基-3-三甲基硅氧基哌啶的甲基叔丁基醚溶液,直接用于下步反应,GC纯度:97.7%(扣除溶剂)。
第二步,在配有磁力搅拌的2L三口瓶内,向上述第一步所得N-苄-3-三甲基硅氧基哌啶溶液中,缓慢滴加160mL乙醇,控温10-20℃,滴毕,室温继续搅拌3小时,GC检测脱保护完全后,水洗,有机层减压浓缩后,加入250mL正庚烷-10~0℃下打浆,过滤得到类白色固体N-苄基-3-羟基哌啶157.2g,两步收率86.5%,熔点25.8-27.2℃,GC纯度99.5%。
实施例3
第一步,在配有磁力搅拌的2L三口瓶内,将3-羟基哌啶(101.2g,1mol)溶于1L四氢呋喃中,加入碳酸钠(265.0g,2.5mol),滴加0.95当量溴化苄(162.5g,0.95mol),加热回流反应4小时,GC中控反应完毕;氮气保护下,加入六甲基二硅基胺烷(322.8g,2mol),升温回流反应2小时,TLC检测反应完毕,展开剂为:正己烷/乙酸乙酯=5∶1,降温,浓缩出溶剂后,减压蒸馏出低沸点物质(42~69℃,2torr),室温下向残余物中加入1.2L甲基叔丁基醚,过滤掉不溶物,滤液为N-苄基-3-三甲基硅氧基哌啶的甲基叔丁基醚溶液,直接用于下步反应,GC纯度:97.6%(扣除溶剂)。
第二步,在配有磁力搅拌的2L三口瓶内,向上述第一步所得N-苄-3-三甲基硅氧基哌啶溶液中,缓慢滴加1.3L 1M四丁基氟化胺四氢呋喃溶液,控温10-20℃,滴毕,室温继续搅拌2小时,GC检测脱保护完全后,水洗,有机层减压浓缩后,加入250mL正庚烷-10~0℃下打浆,过滤得到微黄色固体N-苄基-3-羟基哌啶156.6g,熔点25.2-26.6℃,GC纯度99.6%,两步收率86.2%。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (6)
1.一种N-苄基-3-羟基哌啶的合成方法,其特征在于:在无机碱存在下,3-羟基哌啶和卤代苄反应后,接着加入六甲基二硅基胺烷,得到N-苄基3-三甲基硅氧基哌啶,随后加入醇类溶剂或含氟离子盐反应,得到N-苄基-3-羟基哌啶,具体步骤如下:第一步,将3-羟基哌啶溶于有机溶剂中,加入无机碱,滴加3-羟基哌啶的0.9-0.95当量卤代苄,40~50℃反应;反应结束后,加入六甲基二硅基胺烷,升温至50~100℃反应,减压蒸馏出低沸点物质,向残余物中加入甲基叔丁基醚,过滤掉不溶物,滤液为N-苄基-3-三甲基硅氧基哌啶的甲基叔丁基醚溶液,直接用于下步反应;所述低沸点物质为42~69℃/2torr条件下物质;
第二步,将上述第一步所得N-苄基-3-三甲基硅氧基哌啶缓慢加入醇类溶剂或含氟离子盐脱保护,水洗,有机层减压浓缩后,加入正庚烷-10~0℃下打浆,过滤得到N-苄基-3-羟基哌啶。
2.根据权利要求1所述的一种N-苄基-3-羟基哌啶的合成方法,其特征在于:所述第一步中,有机溶剂选自甲苯、丙酮或四氢呋喃。
3.根据权利要求1所述的一种N-苄基-3-羟基哌啶的合成方法,其特征在于:所述第一步中,卤代苄选自溴苄或氯苄。
4.根据权利要求1所述的一种N-苄基-3-羟基哌啶的合成方法,其特征在于:所述第一步中,无机碱选自碳酸钠、碳酸钾或碳酸铯。
5.根据权利要求1所述的一种N-苄基-3-羟基哌啶的合成方法,其特征在于:所述第一步中,3-羟基哌啶、无机碱和六甲基二硅基胺烷的摩尔比为1:1.5-2.5:1.5-2。
6.根据权利要求1所述的一种N-苄基-3-羟基哌啶的合成方法,其特征在于:所述第二步中,脱保护时所用的醇类溶剂选自甲醇或乙醇;含氟离子盐选自氟化钾或四丁基氟化铵。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711133635.9A CN107652227B (zh) | 2017-11-15 | 2017-11-15 | 一种n-苄基-3-羟基哌啶的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711133635.9A CN107652227B (zh) | 2017-11-15 | 2017-11-15 | 一种n-苄基-3-羟基哌啶的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107652227A CN107652227A (zh) | 2018-02-02 |
CN107652227B true CN107652227B (zh) | 2020-03-31 |
Family
ID=61121586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711133635.9A Active CN107652227B (zh) | 2017-11-15 | 2017-11-15 | 一种n-苄基-3-羟基哌啶的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107652227B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1763007A (zh) * | 2005-08-31 | 2006-04-26 | 复旦大学附属华山医院 | 一种4—乙酰氧基哌啶盐酸盐的制备方法 |
CN103641774A (zh) * | 2013-11-26 | 2014-03-19 | 湖南方盛制药股份有限公司 | 盐酸贝尼地平的制备方法 |
-
2017
- 2017-11-15 CN CN201711133635.9A patent/CN107652227B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1763007A (zh) * | 2005-08-31 | 2006-04-26 | 复旦大学附属华山医院 | 一种4—乙酰氧基哌啶盐酸盐的制备方法 |
CN103641774A (zh) * | 2013-11-26 | 2014-03-19 | 湖南方盛制药股份有限公司 | 盐酸贝尼地平的制备方法 |
Non-Patent Citations (3)
Title |
---|
Nonracemic Bicyclic Lactam Lactones via Regio- and cis-Diastereocontrolled C-H Insertion. Asymmetric Synthesis of (8S,8aS)-Octahydroindolizidin-8-ol and (1S,8aS)-Octahydroindolizidin-1-ol;Andrew G. H. Wee,等;《J. Org. Chem.》;20091007;第74卷;8261-8271,scheme2 * |
Regio- and diastereocontrolled C–H insertion of chiral γ- and δ-lactam diazoacetates. Application to the asymmetric synthesis of (8S,8aS)-8-hydroxyindolizidine;Gao-jun Fan,等;《Chem. Commun.》;20060802;3732-3734 * |
Supporting information;Andrew G. H. Wee,等;《J. Org. Chem.》;20091007;SI-2、SI-3页化合物2a、(S)-3的合成 * |
Also Published As
Publication number | Publication date |
---|---|
CN107652227A (zh) | 2018-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107805205B (zh) | 一种(r)-3-氨基丁醇的制备方法 | |
EP2240441B1 (en) | Process for the preparation of 6-substituted-1-(2h)-isoquinolinones | |
US20100113793A1 (en) | Process for the Preparation of Highly Pure Donepezil | |
JP5746965B2 (ja) | 塩酸ドネペジルの製造方法 | |
CN107652227B (zh) | 一种n-苄基-3-羟基哌啶的合成方法 | |
US20070129549A1 (en) | Stable lamotrigine pharmaceutical compositions and processes for their preparation | |
JP5001151B2 (ja) | 1−ベンジル−4−[(5,6−ジメトキシ−1−インダノン)−2−イリデン]メチルピペリジンの製造法 | |
CN115160148A (zh) | 一种高选择性的合成n-烯丙基苄胺的方法 | |
CN109369442B (zh) | 一种β-N-甲氨基-L-丙氨酸的制备方法 | |
CN114716331A (zh) | 一种盐酸多巴胺的制备方法 | |
CN115403509A (zh) | 一种雷芬那辛中间体的制备方法 | |
CN112250615A (zh) | 一种托法替尼中间体顺式-1-苄基-n,4-二甲基哌啶-3-胺二盐酸盐的制备方法 | |
JP2020070296A (ja) | リナグリプチンの製造法 | |
KR102134179B1 (ko) | 카보네이트를 이용한 시탈로프람 및 에스시탈로프람의 새로운 제조 방법 | |
CN113493388B (zh) | 一种盐酸布替萘芬的合成方法 | |
CN107827811B (zh) | 一种制备n-取代-1,2,3,6-四氢吡啶的方法 | |
CN107805218B (zh) | 一种制备4-Boc-氨基哌啶的方法 | |
CN105646321A (zh) | (s)-3-羟基吡咯烷盐酸盐的制备方法 | |
US6995270B2 (en) | Hydrogenation process | |
CN111484445A (zh) | 合成高纯度乌美溴铵的中间体的方法 | |
CN114436877A (zh) | 一种抗心衰药物沙库巴曲的合成工艺 | |
CN116041280A (zh) | 一种盐酸曲美他嗪的制备方法 | |
CN111606842A (zh) | 一种2-(4-哌啶基)-2-丙醇及其盐酸盐的制备方法 | |
CN117820257A (zh) | 一种具有高含量顺式异构体的匹维溴铵中间体的制备方法 | |
CN112521298A (zh) | 一种利多卡因的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231127 Address after: 034406 guomaoshan Park, donghenan Town, Lingqiu County, Datong City, Shanxi Province (guomaoshan road section, 120km away from the original Daling highway) Patentee after: Shanxi Kubang Biomedical Technology Co.,Ltd. Address before: 201611 room 2207, building 6, 1378 Xingxian Road, Jiading District, Shanghai Patentee before: SHANGHAI HOBOR CHEMICAL Co.,Ltd. |